Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) will participate in two upcoming investor conferences in November–December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will participate in two upcoming investor conferences in November–December 2025. The company will host a fireside chat at the TD Cowen Virtual Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 2:30 PM ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00 PM ET in Miami, FL.
A live webcast and archived replay of both fireside chats will be available on the investors section of www.vorbio.com.
Details
News Market Reaction – VOR
On Nov 7, the day this news came out, VOR closed 1.42% below the previous close.
Data tracked by StockTitan Argus for the Nov 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:
TD Cowen Virtual Immunology & Inflammation Summit
Fireside Chat: Wednesday, November 12, 2025, at 2:30pm ET
8th Annual Evercore Healthcare Conference
Fireside Chat: Tuesday, December 2, 2025, 3:00pm ET
Location: Miami, FL
A live webcast and archived replay of the fireside chats will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.